Breaking News

Argentina Didn't Reach an Agreement With Holdouts: Mediator
Tweet TWEET

Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer

Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer 
GLOSTRUP, DENMARK -- (Marketwired) -- 04/03/13 --  Dako, an Agilent
Technologies Company and worldwide provider of cancer diagnostics,
recently received clearance from the U.S. Food and Drug
Administration to sell FLEX Monoclonal Rabbit Anti-Human Estrogen
Receptor alpha, Clone EP1 in the United States. The clone has been
available in Europe for some time and has enjoyed widespread
acceptance.  
"We are very pleased to now be able to supply our customers in the
United States with this high-quality antibody for estrogen receptor
testing on Dako's Autostainer Link 48," said Karen Balstrup, global
product manager, IHC Reagents, at Dako.  
Research has shown that tumor growth is dependent on the presence of
estrogen, progesterone or both in most breast cancers. Estrogen
receptor (ER) status in breast carcinomas is a validated prognostic
and predictive factor for managing a patient's anti-hormonal therapy.
With this important diagnostic tool from Dako, breast cancer patients
can be confident they are receiving the most effective treatment for
their particular type of breast cancer. 
Clone EP1 shows excellent concordance with the existing ER component
from Dako's ER/PR pharmDx Kit, with an overall agreement of 97.7
percent, a strong indication that pathologists can rely on the
results obtained from using this antibody.  
"Clone EP1 specifically detects nuclear estrogen receptor without
cytoplasmic staining and shows a high degree of concordance (greater
than 95 percent) to existing clones," said Sunil S. Badve, M.D.,
Department of Pathology and Laboratory Medicine, Indiana University.
"Compared with other established ER antibody assays this new clone is
a highly sensitive and specific antibody." 
The Monoclonal Rabbit Anti-Human ER alpha, Clone EP1 was created by
Epitomics Inc., using Epitomics' proprietary rabbit monoclonal
antibody technology covered under Patent Nos. 5,675,063 and
7,402,409. Dako and Epitomics entered into a collaboration in 2011
which allows the companies to unite competencies to provide the
anatomic pathology market with state-of-the-art antibodies.  
About Dako - An Agilent Technologies Company
 Dako, based in Denmark,
is a global leader in tissue-based cancer diagnostics. Hospital and
research laboratories worldwide use Dako's reagents, instruments,
software and expertise to make accurate diagnoses and determine the
most effective treatment for cancer patients. Dako, with 1,200
employees, operates in more than 100 countries. Dako became part of
Agilent Technologies on June 21, 2012. Information about Dako is
available at www.dako.com.  
About Agilent Technologies
 Agilent Technologies Inc. (NYSE: A) is
the world's premier measurement company and a technology leader in
chemical analysis, life sciences, diagnostics, electronics and
communications. The company's 20,500 employees serve customers in
more than 100 countries. Agilent had revenues of $6.9 billion in
fiscal 2012. Information about Agilent is available at
www.agilent.com. 
Press Release pdf: http://hugin.info/136715/R/1689765/554670.pdf 
CONTACTS
Dako Products:
Victoria Wadsworth-Hansen 
Dako Denmark A/S
+45 29336980 
Dako Corporate: 
Maia Fredtoft Sochting 
Dako Denmark A/S
+45 25461083